July 2, 2018 Bio/Pharma/CRO Licensing, IP, and Legal PR/Corporate

Phase III IMpassion130 study showed Roche’s Tecentriq plus Abraxane significantly reduced the risk of disease worsening or death in people with metastatic triple negative breast cancer

Basel, 02 July 2018 Phase III IMpassion130 study showed Roche’s Tecentriq plus Abraxane significantly reduced the risk of disease worsening or death in people with metastatic triple negative breast cancer First Phase III immunotherapy study to demonstrate a statistically significant improvement in progression-free survival (PFS) in the intention-to-treat (ITT) and PD-L1 positive first-line metastatic triple... Read more

June 29, 2018 Bio/Pharma/CRO

Roche’s RoActemra gains positive CHMP opinion for CAR T-cell-induced cytokine release syndrome

Basel, 29 June 2018 Roche’s RoActemra gains positive CHMP opinion for CAR T-cell-induced cytokine release syndrome Cytokine release syndrome (CRS), a severe and life-threatening condition, is caused by an overactive immune response and is often associated with the use of chimeric antigen receptor (CAR) T-cell therapy for certain blood cancers RoActemra would be the first... Read more

June 28, 2018 Bio/Pharma/CRO M&A, Partnerships PR/Corporate

Agilent Technologies to Expand Biopharma Consumables Portfolio with Acquisition of ProZyme

Highlights: Highly synergistic with Agilent’s current customer-base and sales channel Enables complete LC and LC/MS workflow solutions in important glycan biopharma segment Strengthens Agilent’s customer value proposition in fast-growing biopharma market SANTA CLARA, Calif.–(BUSINESS WIRE)–Jun. 28, 2018– Agilent Technologies Inc. (NYSE: A) today announced that it has entered into a definitive agreement to acquire privately-held ProZyme,... Read more

June 28, 2018 Bio/Pharma/CRO M&A, Partnerships PR/Corporate

Agilent Technologies to Expand Biopharma Consumables Portfolio with Acquisition of ProZyme

Highlights: Highly synergistic with Agilent’s current customer-base and sales channel Enables complete LC and LC/MS workflow solutions in important glycan biopharma segment Strengthens Agilent’s customer value proposition in fast-growing biopharma market SANTA CLARA, Calif.–(BUSINESS WIRE)–Jun. 28, 2018– Agilent Technologies Inc. (NYSE: A) today announced that it has entered into a definitive agreement to acquire privately-held ProZyme,... Read more

June 28, 2018 Bio/Pharma/CRO M&A, Partnerships PR/Corporate

Agilent Technologies to Expand Biopharma Consumables Portfolio with Acquisition of ProZyme

Highlights: Highly synergistic with Agilent’s current customer-base and sales channel Enables complete LC and LC/MS workflow solutions in important glycan biopharma segment Strengthens Agilent’s customer value proposition in fast-growing biopharma market SANTA CLARA, Calif.–(BUSINESS WIRE)–Jun. 28, 2018– Agilent Technologies Inc. (NYSE: A) today announced that it has entered into a definitive agreement to acquire privately-held ProZyme,... Read more

June 25, 2018 Bio/Pharma/CRO

Roche’s TECENTRIQ in combination with chemotherapy helped people with previously-untreated extensive-stage small cell lung cancer live significantly longer compared to chemotherapy

Basel, 25 June 2018 Roche’s TECENTRIQ in combination with chemotherapy helped people with previously-untreated extensive-stage small cell lung cancer live significantly longer compared to chemotherapy IMpower133 is the first Phase III study with an immunotherapy-based combination to show improvement in overall survival and progression-free survival in the initial treatment of extensive-stage small cell lung cancer... Read more

June 13, 2018 Acad, Gov/Utilities Bio/Pharma/CRO

FDA approves Roche’s Avastin (bevacizumab) plus chemotherapy as a treatment for women with advanced ovarian cancer following initial surgery

Basel, 13 June 2018 FDA approves Roche’s Avastin (bevacizumab) plus chemotherapy as a treatment for women with advanced ovarian cancer following initial surgery Avastin is now approved for ten distinct uses across six different types of cancer in the United States Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug... Read more

June 12, 2018 Acad, Gov/Utilities Bio/Pharma/CRO Clinical Research/Diagn. Lab Top-10

Agilent Companion Diagnostic Gains Expanded FDA Approval in Cervical Cancer

Agilent Companion Diagnostic Gains Expanded FDA Approval in Cervical Cancer PD-L1 IHC 22C3 pharmDx can now be used as an aid to identify cervical cancer patients for treatment with KEYTRUDA® (pembrolizumab) SANTA CLARA, Calif., June 12, 2018 Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved its... Read more

June 12, 2018 Bio/Pharma/CRO Lab Top-10

Merck KGaA, Darmstadt, Germany Provides Update on Tepotinib Phase II Results in Advanced Hepatocellular Carcinoma

Primary endpoints met in two clinical trials for investigational targeted therapy, tepotinib, as a monotherapy in MET-positive, advanced hepatocellular carcinoma (HCC) with Child-Pugh Class A liver function These data provide further evidence of tepotinib activity in patients with MET-positive advanced cancers Given evolving standard of care in HCC, Merck KGaA, Darmstadt, Germany will assess the... Read more

June 11, 2018 Acad, Gov/Utilities Bio/Pharma/CRO

Roche announces FDA approval for Venclexta plus Rituxan for people with previously treated chronic lymphocytic leukaemia

Basel, 11 June 2018 Roche announces FDA approval for Venclexta plus Rituxan for people with previously treated chronic lymphocytic leukaemia Approval based on phase III MURANO study showing Venclexta plus Rituxan reduced risk of disease progression or death by 81% compared to bendamustine plus Rituxan Roche (SIX: RO, ROG; OTCQX: RHHBY), announced today that the... Read more